nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

07.05.2018 | Guidelines

Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia

verfasst von: Peter J. Nestor, Daniele Altomare, Cristina Festari, Alexander Drzezga, Jasmine Rivolta, Zuzana Walker, Femke Bouwman, Stefania Orini, Ian Law, Federica Agosta, Javier Arbizu, Marina Boccardi, Flavio Nobili, Giovanni Battista Frisoni, for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Aim

To assess the clinical utility of FDG-PET as a diagnostic aid for differentiating Alzheimer’s disease (AD; both typical and atypical forms), dementia with Lewy bodies (DLB), frontotemporal lobar degeneration (FTLD), vascular dementia (VaD) and non-degenerative pseudodementia.

Methods

A comprehensive literature search was conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted on six different diagnostic scenarios using the Delphi method.

Results

The level of empirical study evidence for the use of FDG-PET was considered good for the discrimination of DLB and AD; fair for discriminating FTLD from AD; poor for atypical AD; and lacking for discriminating DLB from FTLD, AD from VaD, and for pseudodementia. Delphi voting led to consensus in all scenarios within two iterations. Panellists supported the use of FDG-PET for all PICOs—including those where study evidence was poor or lacking—based on its negative predictive value and on the assistance it provides when typical patterns of hypometabolism for a given diagnosis are observed.

Conclusion

Although there is an overall lack of evidence on which to base strong recommendations, it was generally concluded that FDG-PET has a diagnostic role in all scenarios. Prospective studies targeting diagnostically uncertain patients for assessing the added value of FDG-PET would be highly desirable.

Nobili F, Arbizu J, Bouwman F, Drzezga A, Filippi M, Nestor P, et al. EAN-EANM recommendations for the use of brain 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol Eur J. 2018; being submitted.

Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, et al. Assessing accuracy diagnostic FDG-PET studies to define clinical use for dementia diagnosis. J Nucl Med Mol Imaging. 2018; In this Issue.

Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol. 2013;20:410–9. https://doi.org/10.1111/ene.12043.CrossRefPubMed

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRefPubMed

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 2010;9:1118–27. https://doi.org/10.1016/S1474-4422(10)70223-4.CrossRefPubMed

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. https://doi.org/10.1093/brain/awr179.CrossRefPubMedPubMedCentral

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.CrossRefPubMed

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. https://doi.org/10.1016/j.jalz.2011.03.008.CrossRefPubMedPubMedCentral

10.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. https://doi.org/10.1016/S1474-4422(14)70090-0.CrossRefPubMed

11.

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14. https://doi.org/10.1212/WNL.0b013e31821103e6.CrossRefPubMedPubMedCentral

12.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64. https://doi.org/10.1002/mds.26987.CrossRefPubMedPubMedCentral

13.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89:88–100. https://doi.org/10.1212/WNL.0000000000004058.CrossRefPubMedPubMedCentral

14.

Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol. 2007;6:734–46. https://doi.org/10.1016/S1474-4422(07)70178-3.CrossRefPubMed

15.

Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB, et al. EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol. 2012;19:1487–501. https://doi.org/10.1111/j.1468-1331.2012.03859.x.CrossRef

16.

Bouwman F, Orini S, Gandolfo F, Altomare D, Festari C, Agosta F, et al. Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4034-z.CrossRefPubMedPubMedCentral

17.

Drzezga A, Altomare D, Festari C, Arbizu J, Orini S, Herholz K, et al. Diagnostic utility of FDG-PET in conditions of increased risk for Alzheimer’s disease. Eur J Nucl Med Molec Imaging. 2018. https://doi.org/10.1007/s00259-018-4032-1.CrossRefPubMed

18.

Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG-PET in Parkinson’s disease and atypical Parkinsonisms associated to dementia. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4031-2.CrossRefPubMedPubMedCentral

19.

Arbizu J, Festari C, Altomare D, Walker Z, Bouwman F, Rivolta J, et al. Clinical utility of FDG-PET for the differential diagnosis in MCI. Eur J Nucl Med Mol Imaging. 2018. 2018. https://doi.org/10.1007/s00259-018-4039-7.CrossRefPubMed

20.

Agosta F, Altomare D, Festari C, Orini S, Gandolfo F, Boccardi M, et al. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington’s disease. Eur J Nucl Med Molec Imaging. 2018. https://doi.org/10.1007/s00259-018-4033-0.CrossRefPubMed

21.

Matias-Guiu JA, Cabrera-Martin MN, Moreno-Ramos T, Valles-Salgado M, Fernandez-Matarrubia M, Carreras JL, et al. Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol. 2015;262:1463–72. https://doi.org/10.1007/s00415-015-7738-z.CrossRefPubMed

22.

Schmidtke K, Hull M, Talazko J. Posterior cortical atrophy: variant of Alzheimer’s disease? A case series with PET findings. J Neurol. 2005;252:27–35. https://doi.org/10.1007/s00415-005-0594-5.CrossRefPubMed

23.

Whitwell JL, Lowe VJ, Duffy JR, Strand EA, Machulda MM, Kantarci K, et al. Elevated occipital beta-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry. 2013;84:1357–64. https://doi.org/10.1136/jnnp-2013-305628.CrossRefPubMed

24.

Singh TD, Josephs KA, Machulda MM, Drubach DA, Apostolova LG, Lowe VJ, et al. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy. J Neurol. 2015;262:1483–92. https://doi.org/10.1007/s00415-015-7732-5.CrossRefPubMedPubMedCentral

25.

Cerami C, Della Rosa PA, Magnani G, Santangelo R, Marcone A, Cappa SF, et al. Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia. NeuroImage Clin. 2015;7:187–94. https://doi.org/10.1016/j.nicl.2014.12.004.CrossRefPubMed

26.

Laforce R, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: a retrospective memory clinic study. Am J Alzheimer’s Dis Other Demen. 2010;25:324–32. https://doi.org/10.1177/1533317510363468.CrossRef

27.

Laforce RJ, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer’s pathology. NeuroImage Clin. 2014;4:508–16. https://doi.org/10.1016/j.nicl.2014.03.005.CrossRefPubMedPubMedCentral

28.

Madhavan A, Whitwell JL, Weigand SD, Duffy JR, Strand EA, Machulda MM, et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer’s type. PLoS One. 2013;8:e62471. https://doi.org/10.1371/journal.pone.0062471.CrossRefPubMedPubMedCentral

29.

Spehl TS, Hellwig S, Amtage F, Weiller C, Bormann T, Weber WA, et al. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer’s disease--a [F-18]-FDG pet study. J Neuroimaging. 2015;25:281–8. https://doi.org/10.1111/jon.12104.CrossRefPubMed

30.

Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462–6.CrossRefPubMed

31.

Garibotto V, Montandon ML, Viaud CT, Allaoua M, Assal F, Burkhard PR, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med. 2013;38:e112–7. https://doi.org/10.1097/RLU.0b013e318279b991.CrossRefPubMed

32.

Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazuai H, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport. 1999;10:1903–7.CrossRefPubMed

33.

Imamura T, Ishii K, Hirono N, Hashimoto M, Tanimukai S, Kazui H, et al. Occipital glucose metabolism in dementia with lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord. 2001;12:194–7. https://doi.org/10.1159/000051257.CrossRefPubMed

34.

Teune LK, Bartels AL, de Jong BM, Willemsen ATM, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395–404. https://doi.org/10.1002/mds.23291.CrossRefPubMed

35.

Tripathi M, Dhawan V, Peng S, Kushwaha S, Batla A, Jaimini A, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology. 2013;55:483–92. https://doi.org/10.1007/s00234-012-1132-7.CrossRefPubMed

36.

Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, et al. Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin. 2014;6:445–54. https://doi.org/10.1016/j.nicl.2014.10.009.CrossRefPubMedPubMedCentral

37.

Ishii K, Hosokawa C, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, et al. Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition. Ann Nucl Med. 2015;29:78–83. https://doi.org/10.1007/s12149-014-0911-0.CrossRefPubMed

38.

Granert O, Drzezga AE, Boecker H, Perneczky R, Kurz A, Gotz J, et al. Metabolic topology of neurodegenerative disorders: influence of cognitive and motor deficits. J Nucl Med. 2015;56:1916–21. https://doi.org/10.2967/jnumed.115.156067.CrossRefPubMed

39.

Sharma R, Tripathi M, D’Souza MM, Jaimini A, Varshney R, Panwar P, et al. Spectrum of neurocognitive dysfunction in Indian population on FDG PET/CT imaging. Indian J Nucl Med. 2011;26:67–77. https://doi.org/10.4103/0972-3919.90255.CrossRefPubMedPubMedCentral

40.

Kasanuki K, Iseki E, Fujishiro H, Yamamoto R, Higashi S, Minegishi M, et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci. 2012;314:111–9. https://doi.org/10.1016/j.jns.2011.10.010.CrossRefPubMed

41.

Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575–93. https://doi.org/10.1007/s12021-014-9235-4.CrossRefPubMed

42.

Chiba Y, Fujishiro H, Ota K, Kasanuki K, Arai H, Hirayasu Y, et al. Clinical profiles of dementia with Lewy bodies with and without Alzheimer’s disease-like hypometabolism. Int J Geriatr Psychiatry. 2015;30:316–23. https://doi.org/10.1002/gps.4144.CrossRefPubMed

43.

Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235:49–52.CrossRefPubMed

44.

Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2001;25:447–56.CrossRef

45.

Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Differentiation of Alzheimer’s disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005;191(Suppl):S95–103. https://doi.org/10.1016/j.expneurol.2004.06.017.CrossRefPubMed

46.

Firbank MJ, Lloyd J, Williams D, Barber R, Colloby SJ, Barnett N, et al. An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer’s disease according to presence of medial temporal lobe atrophy. Br J Psychiatry. 2016;208:491–6. https://doi.org/10.1192/bjp.bp.114.160804.CrossRefPubMed

47.

Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol. 2000;162:247–56. https://doi.org/10.1006/exnr.2000.7342.CrossRefPubMed

48.

Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease. J Nucl Med. 2007;48:704–11. https://doi.org/10.2967/jnumed.106.035691.CrossRefPubMed

49.

Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936–44.PubMed

50.

Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50:1638–45. https://doi.org/10.2967/jnumed.109.065870.CrossRefPubMed

51.

Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358–65.CrossRefPubMed

52.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49:390–8. https://doi.org/10.2967/jnumed.107.045385.CrossRefPubMed

53.

O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med. 2014;55:1959–65. https://doi.org/10.2967/jnumed.114.143347.CrossRefPubMed

54.

Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2007;34:1490–7. https://doi.org/10.1007/s00259-007-0380-y.CrossRefPubMed

55.

Santens P, De Bleecker J, Goethals P, Strijckmans K, Lemahieu I, Slegers G, et al. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D-glucose in Alzheimer’s disease and frontotemporal dementia at initial diagnosis. Eur Neurol. 2001;45:19–27. https://doi.org/10.1159/000052084.CrossRefPubMed

56.

Tripathi M, Tripathi M, Damle N, Kushwaha S, Jaimini A, D’Souza MM, et al. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT. Neuroradiol J. 2014;27:13–21. https://doi.org/10.15274/NRJ-2014-10002.CrossRefPubMedPubMedCentral

57.

Panegyres PK, Rogers JM, McCarthy M, Campbell A, Wu JS. Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol. 2009;9:41. https://doi.org/10.1186/1471-2377-9-41.CrossRefPubMedPubMedCentral

58.

Bergeron D, Beauregard J-M, Guimond J, Fortin M-P, Houde M, Poulin S, et al. Clinical impact of a second FDG-PET in atypical/unclear dementia syndromes. J Alzheimers Dis. 2016;49:695–705. https://doi.org/10.3233/JAD-150302.CrossRefPubMed

59.

Krudop WA, Dols A, Kerssens CJ, Prins ND, Moller C, Schouws S, et al. Impact of imaging and cerebrospinal fluid biomarkers on behavioral variant frontotemporal dementia diagnosis within a late-onset frontal lobe syndrome cohort. Dement Geriatr Cogn Disord. 2016;41:16–26. https://doi.org/10.1159/000441023.CrossRefPubMed

60.

Kerklaan BJ, van Berckel BNM, Herholz K, Dols A, van der Flier WM, Scheltens P, et al. The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2014;29:607–13. https://doi.org/10.1177/1533317514524811.CrossRefPubMed

61.

Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130:2616–35. https://doi.org/10.1093/brain/awm177.CrossRefPubMed

62.

Poljansky S, Ibach B, Hirschberger B, Männer P, Klünemann H, Hajak G, et al. A visual [18F]FDG-PET rating scale for the differential diagnosis of frontotemporal lobar degeneration. Eur Arch Psychiatry Clin Neurosci. 2011;261:433–46. https://doi.org/10.1007/s00406-010-0184-0.CrossRefPubMed

63.

Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42. https://doi.org/10.1212/WNL.0b013e31823b9c5e.CrossRefPubMedPubMedCentral

64.

Perani D, Cerami C, Caminiti SP, Santangelo R, Coppi E, Ferrari L, et al. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging. 2016;43:499–508. https://doi.org/10.1007/s00259-015-3170-y.CrossRefPubMed

65.

Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–9. https://doi.org/10.2967/jnumed.110.082057.CrossRefPubMed

66.

Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39:1875–8.PubMed

67.

Iaccarino L, Crespi C, Della Rosa PA, Catricala E, Guidi L, Marcone A, et al. The semantic variant of primary progressive aphasia: clinical and neuroimaging evidence in single subjects. PLoS One. 2015;10:e0120197. https://doi.org/10.1371/journal.pone.0120197.CrossRefPubMedPubMedCentral

68.

De Reuck J, Decoo D, Marchau M, Santens P, Lemahieu I, Strijckmans K. Positron emission tomography in vascular dementia. J Neurol Sci. 1998;154:55–61.CrossRefPubMed

69.

Sabri O, Hellwig D, Schreckenberger M, Cremerius U, Schneider R, Kaiser HJ, et al. Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. J Nucl Med. 1998;39:147–54.PubMed

70.

Mendez MF, Ottowitz W, Brown CV, Cummings JL, Perryman KM, Mandelkern MA. Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on (18)FDG-PET imaging. Dement Geriatr Cogn Disord. 1999;10:518–25. https://doi.org/10.1159/000017199.CrossRefPubMed

71.

Sultzer DL, Mahler ME, Cummings JL, Van Gorp WG, Hinkin CH, Brown C. Cortical abnormalities associated with subcortical lesions in vascular dementia. Clinical and position emission tomographic findings. Arch Neurol. 1995;52:773–80.CrossRefPubMed

72.

Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, et al. Can PET data differentiate Alzheimer’s disease from vascular dementia? Ann N Y Acad Sci. 2000;903:252–61.CrossRefPubMed

73.

Hoffmann M. Frontal network syndrome testing: clinical tests and positron emission tomography brain imaging help distinguish the 3 most common dementia subtypes. Am J Alzheimers Dis Other Demen. 2013;28:477–84. https://doi.org/10.1177/1533317513488920.CrossRefPubMed

74.

Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ. Effects of white matter lesions and lacunes on cortical function. Arch Neurol. 2004;61:1545–50. https://doi.org/10.1001/archneur.61.10.1545.CrossRefPubMed

75.

Kuczynski B, Reed B, Mungas D, Weiner M, Chui HC, Jagust W. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch Neurol. 2008;65:650–5. https://doi.org/10.1001/archneur.65.5.650.CrossRefPubMedPubMedCentral

76.

Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron J-C. 18FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26:1213–21. https://doi.org/10.1038/sj.jcbfm.9600296.CrossRefPubMed

77.

Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med. 1994;21:1052–60.CrossRefPubMed

78.

Seo SW, Cho SS, Park A, Chin J, Na DL. Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging. 2009;19:213–9. https://doi.org/10.1111/j.1552-6569.2008.00292.x.CrossRefPubMed

79.

Duara R, Barker W, Loewenstein D, Pascal S, Bowen B. Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer’s disease and multi-infarct dementia. Eur Neurol. 1989;29(Suppl 3):9–15.CrossRefPubMed

80.

Szelies B, Mielke R, Herholz K, Heiss WD. Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr Clin Neurophysiol. 1994;91:131–9.CrossRefPubMed

81.

Kipps CM, Hodges JR, Fryer TD, Nestor PJ. Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: refining the clinical phenotype. Brain. 2009;132:2566–78. https://doi.org/10.1093/brain/awp077.CrossRefPubMed

82.

Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10. https://doi.org/10.1007/s00259-009-1264-0.CrossRefPubMed

83.

Caso F, Gesierich B, Henry M, Sidhu M, LaMarre A, Babiak M, et al. Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick’s disease pathology. Behav Neurol. 2013;26:95–106. https://doi.org/10.3233/BEN-2012-120255.CrossRefPubMedPubMedCentral

84.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes. JAMA. 2015;313:1939. https://doi.org/10.1001/jama.2015.4669.CrossRefPubMedPubMedCentral

85.

Walker Z, Jaros E, Walker RWH, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81. https://doi.org/10.1136/jnnp.2006.110122.CrossRefPubMedPubMedCentral

86.

Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry. 2012;83:1063–70. https://doi.org/10.1136/jnnp-2012-302577.CrossRefPubMed

87.

Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol. 2008;21:157–63. https://doi.org/10.1097/WNN.0b013e3181864a09.CrossRefPubMed

88.

Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42:2672–713. https://doi.org/10.1161/STR.0b013e3182299496.CrossRefPubMedPubMedCentral

Titel: Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia
verfasst von: Peter J. Nestor
Daniele Altomare
Cristina Festari
Alexander Drzezga
Jasmine Rivolta
Zuzana Walker
Femke Bouwman
Stefania Orini
Ian Law
Federica Agosta
Javier Arbizu
Marina Boccardi
Flavio Nobili
Giovanni Battista Frisoni
for the EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders
Publikationsdatum: 07.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4035-y

Springer Medizin

Abstract

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2018

Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia

Brain FDG-PET: clinical use in dementing neurodegenerative conditions

Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer’s disease

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain

Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience